Nachrichten zur Neurocrine Biosciences Inc. Aktie

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which…

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II…

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today…

Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Looks Like A Long-Term Value After Share Price Decline

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present…

Neurocrine Bio to discuss data from movement disorder programs at scientific meetings between Sept. 10 - 16

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference

SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Citi 15 …

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript

NBIX earnings call for the period ending June 30, 2020....…

Neurocrine Biosciences, Inc. 2020 Q2 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Top Analyst Upgrades and Downgrades: Charter, Clorox, FirstEnergy, Neurocrine, RingCentral, Roku, Seagate, Take-Two, Zillow and More

Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ingrezza Remains Surprisingly Strong For Neurocrine

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

How Neurocrine Biosciences Crushed It in Q2

The biotech blew past Wall Street estimates with soaring sales of Ingrezza....…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the…

NEUROCRINE BIOSCIENCES INC: 10-Q Report

10-Q...…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences Reports Second Quarter 2020 Financial Results

SAN DIEGO , Aug. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today…

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020

SAN DIEGO , July 30, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

SAN DIEGO , July 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced…

Neurocrine Further Expands Its Pipeline With An Early-Stage Deal

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Takeda, Neurocrine sign $2bn deal on potential therapies for psychiatric disorders

Under the strategic collaboration, the companies will develop and commercialise compounds in Takedas early-to-mid-stage psychiatry pipeline. As part of the…

Neurocrine Biosciences und Takeda kündigen Zusammenarbeit bei der Entwicklung und Vermarktung möglicher Therapien für psychische Störungen an

SAN DIEGO und OSAKA, Japan--(BUSINESS WIRE)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX) und die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda”) gaben heute eine…

Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference

SAN DIEGO , June 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will…

Full Phase II Data Reinforces Crinecerfont As A Serious Opportunity For Neurocrine Biosciences

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences started at outperform with $147 stock price target at Wedbush

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

Um den gesamten Artikel unter barchart.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast

SAN DIEGO , June 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present…

FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women

NORTH CHICAGO, Ill. , May 29, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with…